CROSSJECT Email Format
Pharmaceutical ManufacturingBourgogne-franche-comté, France51-200 Employees
CROSSJECT is a pharmaceutical manufacturing company with operations in France and the United States, employing 51-200 people and headquartered at 6-8 Rue Pauline Kergomard in Dijon, Bourgogne-Franche-Comté, France. Crossject SA is listed on Euronext under the ticker ALCJ. It is in advanced regulatory development for ZEPIZURE, an epileptic rescue therapy, and has a contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE is based on the needle-free autoinjector ZENEO, designed to enable emergency delivery of medication via intramuscular injection on bare skin or through clothing. The company also has additional products in development, including rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose, and asthma attacks.